Growth Portfolio — Total Revenues
Bristol-Myers Squibb Growth Portfolio — Total Revenues increased by 4.0% to $6.86B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 18.0%, from $5.81B to $6.86B. Over 2 years (FY 2022 to FY 2024), Growth Portfolio — Total Revenues shows an upward trend with a 16.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration and strong demand for the company's newest drug launches, while a decrease may signal competitive pressure or slower-than-expected adoption of new therapies.
Detailed definition
This metric represents the aggregate net sales generated by a company's portfolio of newer, high-growth pharmaceutical p...
Peer comparison
Peers in the biopharmaceutical industry typically report similar metrics under labels like 'New Product Revenue' or 'Growth Portfolio Sales' to highlight the transition from legacy assets to next-generation therapies.
bmy_segment_growth_portfolio_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.19B | $4.19B | $4.19B | $4.19B | $4.42B | $4.74B | $4.95B | $5.26B | $4.79B | $5.60B | $5.81B | $6.36B | $5.56B | $6.60B | $6.86B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +5.5% | +7.4% | +4.3% | +6.3% | -8.9% | +16.8% | +3.9% | +9.5% | -12.6% | +18.6% | +4.0% |
| YoY Change | — | — | — | — | +5.5% | +13.2% | +18.1% | +25.5% | +8.5% | +18.0% | +17.5% | +21.0% | +16.1% | +17.9% | +18.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's growth portfolio — total revenues?
- Bristol-Myers Squibb (BMY) reported growth portfolio — total revenues of $6.86B in Q3 2025.
- How has Bristol-Myers Squibb's growth portfolio — total revenues changed year-over-year?
- Bristol-Myers Squibb's growth portfolio — total revenues increased by 18.0% year-over-year, from $5.81B to $6.86B.
- What is the long-term trend for Bristol-Myers Squibb's growth portfolio — total revenues?
- Over 2 years (2022 to 2024), Bristol-Myers Squibb's growth portfolio — total revenues has grown at a 16.0% compound annual growth rate (CAGR), from $16.76B to $22.56B.
- What does growth portfolio — total revenues mean?
- The total revenue generated by the company's newest and fastest-growing pharmaceutical products.